Regeneron Pharmaceuticals (REGN) Earnings Date & Reports

Key Takeaways

• Total revenues reached $5,116 million in the third quarter of 2026, a 36% increase from $3,754 million in the prior-year period.
• Diluted earnings per share (EPS) from continuing operations rose to $18.45, while non-GAAP (non-Generally Accepted Accounting Principles) EPS grew approximately 70% year over year.
• Dupixent, EYLEA HD, and Libtayo each set new all-time highs for quarterly net sales for the second consecutive quarter.
• Net income climbed to $1,948.7 million from $1,460 million a year earlier, driven by strong commercial execution and higher collaboration revenue.
• Research and development (R&D) spending increased 22% to $1,795 million, reflecting pipeline advancement and manufacturing activity.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for this ticker.
• Interested in automated trading ideas? Explore Trending AI Robots to see AI-driven signals in action.

Earnings Context and Why It Matters

Regeneron's third quarter 2026 report carries weight for investors because it tests whether the company's diversified growth story can sustain momentum beyond its flagship Dupixent franchise. The quarter marked a third consecutive period of double-digit top- and bottom-line growth, underscoring the strength of its commercial portfolio. Dupixent, reported by partner Sanofi, posted global net sales of roughly $6.5 billion, while the EYLEA HD transition continued reshaping the ophthalmology business. With competitive pressure on the legacy EYLEA franchise and rising R&D investment, this report offers a clear read on whether newer products such as Libtayo and pipeline catalysts can offset maturing assets.

Reported Results

Regeneron reported total revenues of $5,116 million for the third quarter of 2026, up 36% from $3,754 million a year earlier, comfortably ahead of the consensus expectation of roughly $4.54 billion. Net product sales rose 14% to $1,805 million. Sanofi collaboration revenue increased 68% to $2,724 million, boosted by a higher share of profits from Dupixent and the full repayment of the Sanofi Development Balance earlier in 2026.

On the bottom line, net income was $1,948.7 million versus $1,460 million in the prior-year period. Diluted EPS from continuing operations was $18.45, compared with $13.62 a year ago. Non-GAAP EPS grew approximately 70% year over year to around $20, well above the analyst consensus near $16.25, according to Yahoo Finance data.

Product-level results were mixed but broadly positive. EYLEA HD U.S. net sales jumped 62% to $699 million, while legacy EYLEA fell 41% to $400 million as patients transitioned to the newer formulation. Libtayo global net sales climbed 51% to $550 million, and U.S. sales grew 81% to $396 million. Dupixent global net sales, reported by Sanofi, reached a record $6.5 billion, up 35% at constant currency.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those monitoring events like Regeneron's quarterly earnings, it offers a structured way to surface actionable candidates across the broader market.

Market Reaction and Investor Sentiment

Heading into the report, sentiment was cautiously optimistic, with analysts focused on whether Dupixent's strength could offset continued pressure on the legacy EYLEA franchise. The significant revenue and EPS beats, combined with record sales across the three core growth brands, provided a clear positive surprise relative to expectations. Investor attention centered on the durability of Dupixent's growth, the accelerating EYLEA HD transition, and Libtayo's momentum in oncology. The higher R&D spend signaled ongoing investment in the pipeline, a trade-off that investors generally viewed favorably given the breadth of late-stage catalysts.

Forward Outlook and Key Factors to Monitor

Looking ahead, several catalysts could shape Regeneron's trajectory. An FDA (U.S. Food and Drug Administration) decision on cemdisiran for generalized myasthenia gravis is expected in November 2026. If approved, it would be the first siRNA (small interfering RNA) therapy for the condition, offering quarterly subcutaneous dosing.

The company also expects a decision on an EYLEA HD prefilled syringe before the end of the year, which management believes could drive further adoption. In metabolic disease, initial data for the CIDEB-targeting siRNA showed a roughly 70% reduction in liver fat in 12 weeks, with more details expected at an upcoming liver meeting.

Investors should also monitor the expanded Sanofi collaboration, announced in October 2026, which added next-generation long-acting antibodies with a $1.0 billion upfront payment and up to $7.0 billion in potential milestones. Rising R&D costs, competitive dynamics in ophthalmology, and the pace of pipeline readouts remain key variables to watch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations